Text Size

Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs

This study has been completed.
Sponsor:
Information provided by:
Nihon University
ClinicalTrials.gov Identifier:
NCT01271426
First received: January 5, 2011
Last updated: NA
Last verified: January 2011
History: No changes posted
  Purpose

To determine whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (PCV) with ranibizumab.


Condition
Polypoidal Choroidal Vasculopathy

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Association of Complement Factor H and ARMS2 Genotypes With Response of Polypoidal Choroidal Vasculopathy to Intravitreal Ranibizumab

Resource links provided by NLM:

Drug Information available for: Ranibizumab
U.S. FDA Resources

Further study details as provided by Nihon University:

Primary Outcome Measures:
  • Association of Complement Factor H and ARMS2 Genotypes with Response of Polypoidal Choroidal Vasuculopathy to Intravitral Ranibizumab [ Time Frame: a month after injection ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   Samples With DNA

white blood cell


Enrollment: 74
Study Start Date: April 2008
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

outpatients in hospital

Criteria

Inclusion Criteria:

  • Clinical diagnosis of Polypoidal choroidal vasculopathy
  • must have injection of Ranibizumab

Exclusion Criteria:

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01271426

Locations
Japan
Surugadai Nihon university hospital
1-8-13 Kandasurugadai Chiyoda-ku, Tokyo, Japan, 101-8309
Sponsors and Collaborators
Nihon University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01271426     History of Changes
Other Study ID Numbers: NihonU-1
Study First Received: January 5, 2011
Last Updated: January 5, 2011
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Nihon University:
Polypoidal Choroidal Vasculopathy
Ranibizumab

ClinicalTrials.gov processed this record on May 21, 2013